PRADAXA (DABIGATRAN EXTILATE) has been the subject of TV, print and other advertising by the manufacturer BOEHRINGER INGELHEIM. PRADAXA CASES involving fatalities and serious complications have only become the focus of media attention since November 2011, a year after the U.S. Food & Drug Administration (FDA) approved the drug. Following international health authorities in Europe, Australia & Japan voicing their concerns over increased risks, FDA issued a safety alert in December 2011. The promotion video below is available on YouTube and was posted in November 2011.

In March 2012, media scrutiny was renewed on reports of a death in Utah (discussed here), as well as the publication of a PRADAXA CASE report (discussed here) by attending physicians that witnessed the bleeding death of the patient identified in the case report.

Published reports indicate that with the rise in prescriptions of PRADAXA (DABIGATRAN EXTILATE) there was a marked and rapid rise in reports of adverse events. Given international safety signals and reports of 260 deaths it appears PRADAXA CASES and related bleeding lawsuits will address the issue of whether or not the pills were rushed to market in the United States for use in Atrial Fibrillation (AFib). This indication was only recently granted in the United Kingdom.

The sponsor of this site, Gabriel F. Zambrano, P.A., is actively investigating PRADAXA CASES involving bleeding deaths or serious personal injuries from the use of PRADAXA (DABIGATRAN EXTILATE). A FREE CASE EVALUATION is available from Gabriel F. Zambrano, P.A., is available through use of the contact form below.

PRADAXA® CASES - AFIB INDICATION.